Literature DB >> 2934821

The cost of prescribing in general practice.

F Fitton, B Temple, H W Acheson.   

Abstract

Costs to the National Health Service and to the patients were determined for a sample of 77 patients who had consulted their doctor about back pain, depression or eczema. One of the main costs of the Health Service was for medication. Prescription forms were traced and costed after dispensing. Costs to patients included monetary aspects, side effects of medication and socio-emotional responses to illness. The Nottingham Health Profile was used to measure the latter on a time-scale series. Consultations with patients who had eczema were most likely to result in medication being prescribed. The mean cost of medication throughout the episode of illness was highest for those who had consulted about depression. Patients reported that 59 (61%) of prescribed items resulted in an improvement of the condition. This was likely to occur most often with treatment for eczema and least likely for patients who had back pain. Non-monetary costs, e.g. disruption of social life, were found to be highest in relation to depression.

Entities:  

Mesh:

Year:  1985        PMID: 2934821     DOI: 10.1016/0277-9536(85)90166-2

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  4 in total

1.  General practitioner response to elderly patients discharged from hospital.

Authors:  E I Williams; F Fitton
Journal:  BMJ       Date:  1990-01-20

2.  What is the cost of a prescription?

Authors:  A Jacob
Journal:  J R Coll Gen Pract       Date:  1987-05

Review 3.  The epidemiology and experience of atopic eczema during childhood: a discussion paper on the implications of current knowledge for health care, public health policy and research.

Authors:  M Fennessy; S Coupland; J Popay; K Naysmith
Journal:  J Epidemiol Community Health       Date:  2000-08       Impact factor: 3.710

Review 4.  Understanding economic evidence for the prevention and treatment of atopic eczema.

Authors:  T H Sach; E McManus; N J Levell
Journal:  Br J Dermatol       Date:  2019-04-11       Impact factor: 9.302

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.